Catalyst Pharmaceuticals, Inc. (CPRX) Cash Flow Statement

The consistent ability to convert net income into operating cash flow at a ratio above parity suggests that the company's profitability is not reliant on aggressive revenue recognition or deferred expense accounting. Investors should monitor whether this conversion efficiency persists as the company scales its newer DMD franchise, which may introduce different working capital requirements.

The trajectory of free cash flow remains strong relative to peers, underscoring the company's ability to generate significant liquidity from its core neurology assets. While the recent compression in FCF margins warrants attention, it appears to be a function of strategic growth investment rather than a fundamental deterioration in the underlying business model.

The minimal capital expenditure requirements allow the company to retain the vast majority of its operating cash flow, providing substantial flexibility for future M&A or balance sheet fortification. This structural advantage is a key differentiator against peers that must invest heavily in proprietary manufacturing or clinical trial facilities.

The volatility in working capital appears to be tied to the integration of new product lines and the associated inventory build-up required for commercial expansion. Analysts should investigate whether these swings represent temporary timing mismatches or a permanent shift in the cash conversion cycle as the product portfolio diversifies.